Acute myocardial infarction marker and application thereof

A technology for acute myocardial infarction and product expression, applied in the field of biomedicine, can solve the problem of no acute myocardial infarction, and achieve the effect of simplifying the process of quantitative detection, improving work efficiency and good stability

Active Publication Date: 2016-02-24
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF1 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The inventors performed high-throughput sequencing on the blood samples of 6 cases of acute myocardial infarction and 6 control groups, combined with bioinformatics methods for gene screening, and selected the candidate gene RFX2 with low expression among the genes with obvious differential expression. There is no report on RFX2 and acute myocardial infarction. Further, the inventors carried out molecular verification and confirmed that RFX2 is highly expressed in the acute myocardial infarction group

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acute myocardial infarction marker and application thereof
  • Acute myocardial infarction marker and application thereof
  • Acute myocardial infarction marker and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The collection of embodiment 1 case

[0032] From December 2012 to June 2014, 6 patients with initial acute myocardial infarction in the Department of Cardiovascular Medicine of the hospital were selected. The time from the onset of acute myocardial infarction to admission was 0.5-10 hours. The inclusion criteria were in line with the inclusion criteria for acute myocardial infarction announced at the 2012 ESC Congress. All enrolled patients have signed the informed consent. The healthy controls were 6 healthy subjects from the physical examination center of the hospital, who matched the age and gender of the patients in the experimental group, and related diseases were excluded according to the exclusion criteria of the AMI group. Healthy subjects informed and agreed to participate in the study.

[0033] Inclusion criteria:

[0034] Refer to the new version of the global unified definition of myocardial infarction diagnostic criteria announced at the ESC Conference ...

Embodiment 2

[0054] Example 2 High-throughput sequencing and analysis

[0055] RNA extraction is performed on peripheral blood, followed by agarose gel electrophoresis after RNA extraction. From the results of electrophoresis, it can be preliminarily judged whether the quality of the extracted RNA sample is qualified or not, and whether it can be used for further transcriptome sequencing. Then, the extraction of RNA samples was detected by NanoDrop1000 spectrophotometer, and the sample requirements for RNA-seq sequencing: OD260 / OD280 was 1.8-2.2. The qualified samples were sent to the sequencing company for sequencing. The sequencing platform was the HiSeq2500 high-throughput sequencing platform of Illumina Company for high-throughput transcriptome deep sequencing. The sequencing company provided the results of data analysis and combined with the literature, we screened the differentially expressed gene RFX2.

Embodiment 3

[0056] Embodiment 3 RFX2 gene expression in peripheral blood of patients with acute myocardial infarction group and control group

[0057] 1. Materials and methods

[0058] 1. Materials

[0059] The peripheral blood of 48 cases of patients with acute myocardial infarction and 45 cases of control group were selected and grouped and numbered. The inclusion and exclusion criteria of the two groups refer to Example 1.

[0060] 2. Method

[0061] 2.1 Extraction of peripheral blood RNA in patients with acute myocardial infarction and controls

[0062] leukapheresis

[0063] (1) Take 2m1 anticoagulated peripheral blood (blood collection time does not exceed 3h);

[0064] (2) Add an equal volume of sterile PBS to the peripheral blood and mix thoroughly to form a cell suspension;

[0065] (3) Add 4ml of lymphocyte separation solution to another centrifuge tube;

[0066] (4) Pipette 4m1 of the cell suspension and gently add it to the surface of the lymphocyte separation medium al...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an acute myocardial infarction marker and an application thereof, and in particular relates to RFX2 and an application of an agonist thereof in preparing a medicine for diagnosis and treatment on acute myocardial infarction. Based on a high-flux sequencing result, the inventor screens out the RFX2 gene; a molecular biology method verifies that RFX2 has low expression in the peripheral blood and the cardiac muscle tissue of the acute myocardial infarction. The invention provides the potential diagnosis and treatment target spot of the acute myocardial infarction, and has great clinical application values.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular to an acute myocardial infarction marker and its application, and more specifically to the application of RFX2 and its agonist in the preparation of drugs for the diagnosis and treatment of acute myocardial infarction. Background technique [0002] The incidence of acute myocardial infarction (AMI) has gradually increased in recent years, and tends to be younger. It is one of the main causes of human death today. This disease is common in obese people in European and American countries, and the incidence of this disease in China has also shown a significant upward trend in recent years. At the onset of the disease, the main clinical manifestation is intense and persistent substernal pain, which cannot be relieved by rest or nitroglycerin, accompanied by the increase of serum myocardial necrosis markers and the evolution of dynamic electrocardiogram. The occurrence of acute myocar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G01N33/68A61K45/06A61P9/10
CPCA61K45/06C12Q1/6883G01N33/68G01N2333/46G01N2800/324
Inventor 杨承刚李瑜
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap